StockNews.com Begins Coverage on Check-Cap (NASDAQ:CHEK)

Equities research analysts at StockNews.com initiated coverage on shares of Check-Cap (NASDAQ:CHEK) in a research report issued to clients and investors on Monday. The firm set a “sell” rating on the medical research company’s stock.

Check-Cap Stock Performance

Check-Cap stock opened at $1.23 on Monday. The firm has a market cap of $7.20 million, a price-to-earnings ratio of -0.41 and a beta of 0.17. Check-Cap has a 1 year low of $0.56 and a 1 year high of $3.45. The firm’s 50 day moving average price is $1.02 and its two-hundred day moving average price is $1.45.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.